APC anti-human CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
29E.2A3 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
29E.2A3_APC_CD274_Antibody_FC_091013
PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (B7-H1, PD-L1) (clone 29E.2A3) APC (filled histogram) or mouse IgG2b, κ APC isotype control (open histogram).
  • 29E.2A3_APC_CD274_Antibody_FC_091013
    PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD274 (B7-H1, PD-L1) (clone 29E.2A3) APC (filled histogram) or mouse IgG2b, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
329707 25 tests 111€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329708 100 tests 234€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5. Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). 

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor® 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor® 700 conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Kuryk L, et al. 2019. Oncoimmunology. 8:e1532763. PubMed
  2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  3. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  4. Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  5. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  6. Sapski S, et al. 2020. Cancer Immunol Immunother. 2291:69. PubMed
  7. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  8. Rauch DA, et al. 2019. Blood. 134:1406. PubMed
  9. Sun X, et al. 2020. Am J Cancer Res. 10:564. PubMed
  10. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
  11. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  12. Tanaka C, et al. 2021. Molecules. 26:. PubMed
  13. Hakroush S, et al. 2021. Front Immunol. 11:624547. PubMed
  14. Cen B, et al. 2021. Oncogene. 40:5984. PubMed
  15. Leite NC, et al. 2020. Cell Reports. 32(2):107894.. PubMed
  16. Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed
  17. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  18. Jiang X, et al. 2013. Clin Cancer Res. 19:598. PubMed
  19. Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed
  20. Chou CW, et al. 2020. Am J Cancer Res. 2621:10. PubMed
  21. Li C, et al. 2021. J Immunother Cancer. 9:. PubMed
  22. Shevyrev D, et al. 2021. Exp Ther Med. 209:21. PubMed
  23. Toews K, et al. 2020. Mol Carcinog. 724:59. PubMed
  24. Hsu H, et al. 2016. J Immunol. 197: 1884 - 1892. PubMed
  25. Bernareggi D, et al. 2022. Nat Commun. 13:1899. PubMed
  26. Baleeiro RB, et al. 2022. Oncoimmunology. 11:2080329. PubMed
  27. Chen LM, et al. 2021. Biosci Rep. 41:. PubMed
  28. Boyerinas B, et al. 2015. Cancer Immunol Res. 3: 1148 - 1157. PubMed
  29. Johnson D, et al. 2016. Nat Commun. 7:10582. PubMed
  30. Izmirly AM, et al. 2022. PLoS Pathog. 18:e1009903. PubMed
  31. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  32. Xi X, et al. 2021. Oncol Lett. 22:716. PubMed
  33. Kotetsu Y, et al. 2021. Biomedicines. 9:. PubMed
  34. Miranda A, et al. 2015. Cancer Res . 75: 3032-3042. PubMed
  35. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  36. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  37. Atefi M, et al. 2014. Clin Cancer Res. 20:3446. PubMed
  38. Arlt A, et al. 2020. Mol Oncol. 14:571. PubMed
  39. Yang WH, et al. 2018. Cancer Res. 78:3761. PubMed
  40. Huang BR, et al. 2020. Int J Mol Sci. 21:00. PubMed
  41. Chen LM, et al. 2021. Biosci Rep. Online ahead of print. PubMed
  42. Fu H, et al. 2021. Front Cell Dev Biol. 9:764109. PubMed
  43. Yoshida R, et al. 2022. Cancer Res. :. PubMed
  44. Koopmans I, et al. 2018. Oncoimmunology. 7:e1466016. PubMed
  45. Lim KH, et al. 2020. Nat Commun. 2.889583333. PubMed
  46. Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed
  47. Zhao L, et al. 2018. Oncol Lett. 16:1180. PubMed
  48. Jiao S, et al. 2017. Clin Cancer Res. 23:3711. PubMed
  49. Palakurthi S, et al. 2019. Cancer Immunol Res. 1.303472222. PubMed
  50. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
  51. Wertel I, et al. 2020. J Immunol Res. 1715064:2020. PubMed
  52. Volpin V, et al. 2020. Cancer Immunol Res. 8:1163. PubMed
  53. Li Z, et al. 2020. Front Cell Dev Biol. 8:572689. PubMed
  54. Lin G, et al. 2021. Mol Med Rep. 23:. PubMed
  55. Ofori S, et al. 2019. ACS Omega. 4:12584. PubMed
  56. Jin MH, et al. 2019. Cancer Res Treat. N/A. PubMed
  57. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  58. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  59. Jiang L, et al. 2019. Sci Rep. 9:3705. PubMed
  60. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  61. Gorris MAJ, et al. 2018. J Immunol. 200:347. PubMed
  62. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  63. Wang X, et al. 2022. J Exp Clin Cancer Res. 41:210. PubMed
  64. Tameishi M, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  65. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  66. O'Connor MH, et al. 2021. Commun Biol. 4:563. PubMed
  67. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  68. Zheng Y, et al. 2022. Transl Res. :. PubMed
  69. Hassounah NB, et al. 2019. Cancer Immunol Immunother. 68:407. PubMed
  70. Parent AV, et al. 2021. Cell Reports. 36(7):109538. PubMed
  71. An L, et al. 2016. Sci Rep. 6: 33346. PubMed
  72. Pawlicki JM, et al. 2021. Cancer Res. 81:3241. PubMed
RRID
AB_940358 (BioLegend Cat. No. 329707)
AB_940360 (BioLegend Cat. No. 329708)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD274 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC, IHC-P, Block
Biotin anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PE anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
APC anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Ultra-LEAF™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC, IHC, Block
PE/Cyanine7 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready) 29E.2A3 FC, CyTOF®
Brilliant Violet 711™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 605™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
GoInVivo™ Purified anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC, IHC, Block
PE/Dazzle™ 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 510™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
PerCP/Cyanine5.5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Brilliant Violet 650™ anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Alexa Fluor® 594 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P
TotalSeq™-A0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-B0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-C0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
TotalSeq™-D0007 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 PG
PE/Fire™ 810 anti-human CD274 (B7-H1, PD-L1) Antibody 29E.2A3 FC
PE/Cyanine5 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 FC
Spark YG™ 570 anti-human CD274 (B7-H1, PD-L1) 29E.2A3 IHC-P, FC
Go To Top Version: 7    Revision Date: 11/30/2016

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Purified anti-human CD274 (B7-H1, PD-L1)

  • Biotin anti-human CD274 (B7-H1, PD-L1)

  • PE anti-human CD274 (B7-H1, PD-L1)

  • APC anti-human CD274 (B7-H1, PD-L1)

  • Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1)

  • Ultra-LEAF™ Purified anti-human CD274 (B7-H1, PD-L1)

  • PE/Cyanine7 anti-human CD274 (B7-H1, PD-L1)

  • Purified anti-human CD274 (B7-H1, PD-L1) (Maxpar® Ready)

  • Brilliant Violet 711™ anti-human CD274 (B7-H1, PD-L1)

  • Brilliant Violet 605™ anti-human CD274 (B7-H1, PD-L1)

  • GoInVivo™ Purified anti-human CD274 (B7-H1, PD-L1)

  • PE/Dazzle™ 594 anti-human CD274 (B7-H1, PD-L1)

  • Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1)

  • Brilliant Violet 510™ anti-human CD274 (B7-H1, PD-L1)

  • PerCP/Cyanine5.5 anti-human CD274 (B7-H1, PD-L1)

  • Brilliant Violet 650™ anti-human CD274 (B7-H1, PD-L1)

  • Alexa Fluor® 594 anti-human CD274 (B7-H1, PD-L1)

  • TotalSeq™-A0007 anti-human CD274 (B7-H1, PD-L1)

  • TotalSeq™-B0007 anti-human CD274 (B7-H1, PD-L1)

  • TotalSeq™-C0007 anti-human CD274 (B7-H1, PD-L1)

  • TotalSeq™-D0007 anti-human CD274 (B7-H1, PD-L1)

  • PE/Fire™ 810 anti-human CD274 (B7-H1, PD-L1) Antibody

  • PE/Cyanine5 anti-human CD274 (B7-H1, PD-L1)

  • Spark YG™ 570 anti-human CD274 (B7-H1, PD-L1)

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account